Third Rock, ARCH Venture and Johnson & Johnson led $100m Series A round in Rapport Therapeutics.

Third Rock, ARCH Venture, and Johnson & Johnson, three vebture capital firms, led $100m Series A round in Rapport Therapeutics, a clinical-stage biotechnology company dedicated to the discovery and development of precision medicines for neurological disorders. “Over the past decade, our founding team has investigated the potential power of receptor-associated proteins to enable precision targeting of disease-associated neural circuits and has developed a powerful platform to discover therapeutics for that purpose. RAPs create multiple opportunities to develop new and better options for patients because they enable us both to introduce precision against validated targets and to access currently undruggable receptor types," Reid Huber, Third Rock Ventures Partner.